| Year | Detail |
|---|
| 1996 |
United Therapeutics Corp. was founded by Martine A. Rothblatt on June 26, 1996, and is headquartered in Silver Spring, U.S. |
| 1999 |
United Therapeutics acquires Synquest, Inc., providing in-house capacity and expertise to manufacture treprostinil. |
| 2005 |
The company developed Remodulin, which was approved by 23 countries in the European Union for the treatment of PAH and the improvement of exercise capacity by subcutaneous infusion. |
| 2010 |
The company collaborated with the National Cancer Institute to develop a monoclonal antibody for treating high-risk neuroblastoma, which is today known as Unituxin. |
| 2011 |
United Therapeutics Corporation acquired Revivicor to create a supply of manufactured organs for transplantation. |
| 2014 |
The company signed an agreement with DEKA Research & Development Corp. to develop a next-generation subcutaneous pump for Remodulin, ultimately resulting in the Remunity Pump for Remodulin. |
| 2015 |
The company collaborated with Mayo Clinic to build and operate an ex-vivo lung perfusion center in Jacksonville, Florida. |
| 2022 |
The company launched Tyvaso DPI (treprostinil) inhalation powder, which the FDA approved to improve exercise capacity and treat PAH and PH-ILD. |
| 2023 |
The company acquired IVIVA Medical, Inc., a pre-clinical stage company based in Massachusetts that develops bio-artificially manufactured kidney products. |
